Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

BioXcel Therapeutics (BTAI) Amortization - Deferred Charges (2022 - 2025)

BioXcel Therapeutics has reported Amortization - Deferred Charges over the past 4 years, most recently at $469000.0 for Q4 2025.

  • Quarterly results put Amortization - Deferred Charges at $469000.0 for Q4 2025, up 111.26% from a year ago — trailing twelve months through Dec 2025 was $1.7 million (up 253.96% YoY), and the annual figure for FY2025 was $1.7 million, up 253.75%.
  • Amortization - Deferred Charges for Q4 2025 was $469000.0 at BioXcel Therapeutics, up from $441000.0 in the prior quarter.
  • Over the last five years, Amortization - Deferred Charges for BTAI hit a ceiling of $469000.0 in Q4 2025 and a floor of $43000.0 in Q1 2024.
  • Median Amortization - Deferred Charges over the past 4 years was $322000.0 (2022), compared with a mean of $290200.0.
  • Biggest five-year swings in Amortization - Deferred Charges: tumbled 87.09% in 2024 and later skyrocketed 713.95% in 2025.
  • BioXcel Therapeutics' Amortization - Deferred Charges stood at $322000.0 in 2022, then dropped by 4.66% to $307000.0 in 2023, then fell by 27.69% to $222000.0 in 2024, then skyrocketed by 111.26% to $469000.0 in 2025.
  • The last three reported values for Amortization - Deferred Charges were $469000.0 (Q4 2025), $441000.0 (Q3 2025), and $393000.0 (Q2 2025) per Business Quant data.